Addition of Buserelin to human menopausal gonadotrophins in patients with failed stimulations for IVF or GIFT.
The combined therapy of a gonadotrophin-releasing hormone agonist (GnRHa) D-Ser(TBU)6-EA10-LHRH (Buserelin) and human menopausal gonadotrophins (HMG) for ovarian stimulation for in-vitro fertilization and gamete intra-Fallopian transfer was evaluated during 84 cycles. All women selected for this therapy had previously failed stimulations with clomiphene citrate/HMG. The GnRHa prevented spontaneous luteinizing hormone surges and premature luteinization in all patients. After addition of the agonist to HMG, the cancellation rate dropped from 17 to 7% and improved the results in 72.6% of the cycles. Twenty-six per cent of the started cycles resulted in a pregnancy. Eighteen healthy children were born at term.
Smitz
J
J
Centre for Reproductive Medicine, Vrije Universiteit Brussel, Belgium.
Devroey
P
P
Camus
M
M
Khan
I
I
Staessen
C
C
Van Waesberghe
L
L
Wisanto
A
A
Van Steirteghem
A C
AC
D002064:Buserelin / Q000627:therapeutic use*; D002996:Clomiphene / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004624:Embryo Transfer; D005187:Fallopian Tubes / Q000502:physiology; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008596:Menotropins / Q000627:therapeutic use*; D010062:Ovulation Induction; D011247:Pregnancy
D002996:Clomiphene; D008596:Menotropins; D002064:Buserelin